INSM: Management Raises Long-Term Peak Sales Targets; Seeking Alpha Sees 39% Upside

What happened

Insmed management now projects combined peak sales of $14B+ across its three lead drugs, up 75% from prior estimates, with BRINSUPRI's peak raised to $7B+, according to the Seeking Alpha article. This follows a strong BRINSUPRI launch that delivered $207.9M in Q1 2026 and a reiteration of FY26 guidance of at least $1.0B. However, the company's near-term financials remain strained: SG&A surged 67.6% YoY and operating cash burn was $222.7M in Q1, while the stock trades at $94.17, far below the article's $175 target. The raised peak sales guidance is not yet backed by hard data, and the company's operational leverage timeline is still uncertain, making the long-term projection speculative. Investors are now faced with a narrative that emphasizes massive long-term upside against a backdrop of high near-term execution risk and cash burn.

Implication

For long-term investors, the raised peak sales guidance could expand the bull case if management can demonstrate continued strong BRINSUPRI adoption and evidence that SG&A growth will moderate as launch costs normalize. However, the current $14B+ combined peak sales estimate is not data-backed, and historical biotech guidance often proves optimistic, so the $175 target may be aggressive. Near-term, the key metrics to monitor are sequential BRINSUPRI net sales growth beyond Q1's $207.9M and whether SG&A expenses decline relative to revenue in the next two quarters. The stock's current price of $94.17 is below the DeepValue base case of $110, suggesting the market is still pricing in execution risk and not yet giving credit for the higher peak sales potential. Investors should wait for confirmation of operating leverage or a successful ARIKAYCE sNDA filing before adopting the more bullish outlook, as failure to control costs could derail the long-term value creation story.

Thesis delta

The core thesis remains intact but is now augmented by management's materially higher peak sales expectations for BRINSUPRI and the overall portfolio. However, these projections lack data support and introduce a new layer of optimism that must be validated. The near-term focus on SG&A leverage and BRINSUPRI demand quality is unchanged, but the potential upside beyond the prior $145 bull case now depends on the credibility of the new $14B+ peak sales claim.